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Abstract
Targeted mutation assessment of 81 genes in 1,021 adults with de novo acute myeloid leukemia 
(AML) identified recurrent mutations in the neurofibromin 1 (NF1) gene in 52 (5.1%) patients, 
including 36 (5.2%) younger and 16 (4.8%) older patients, which suggests NF1 belongs to the 20 
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most frequently mutated genes in adult AML. NF1 mutations were found throughout the gene, and 
comprised missense, frame-shift and nonsense mutations. One mutation hotspot, at amino acid 
threonine 676 (Thr676), was found in 27% of AML patients with NF1 mutations. NF1-mutated 
patients belonged more often to the adverse European LeukemiaNet (ELN) risk category than NF1 
wild-type patients. Among patients aged <60 years, the presence of NF1 Thr676 mutations was 
associated with lower complete remission (CR) rates (P=0.04) and shorter overall survival (OS; 
P=0.01), as was the presence of any NF1 mutation in patients in the adverse ELN risk category 
(CR, P=0.05; OS, P<0.001). CR rates were also lower in NF1-mutated patients aged ≥60 years 
compared with NF1 wild-type patients (P=0.001). In summary, our findings provide novel insights 
into the frequency of NF1 mutations in AML, and are suggestive of an adverse prognostic impact 
in patients treated with standard chemotherapy.
INTRODUCTION
The neurofibromin 1 gene (NF1), located at 17q11.2, encodes the RAS GTPase activating 
protein neurofibromin.1,2 Mutations in NF1 affect the RAS-MAPK-signaling pathway,1,2 
and the neurofibromin/RAS-GTPase connection has a crucial role in controlling cell growth 
and proliferation.3 Germline loss-of-function mutations in NF1 are the molecular cause for 
neurofibromatosis type 1 (also known as von Recklinghausen disease),4 an autosomal-
dominant inherited disorder belonging to the so called “cancer predisposition syndromes.”4,5 
Neurofibromatosis type 1 is phenotypically characterized by the presence of café au lait 
spots, Lisch nodules in the eye, and a highly increased incidence of benign and malignant 
tumors, including fibromatous skin tumors. Over 1,000 pathogenic variants of NF1 are listed 
in the Human Gene Mutation Database, and include nonsense mutations, amino acid 
substitutions (missense mutations) and most commonly sizeable truncations of NF1 due to 
frameshift mutations. The observation that children carrying germline NF1 mutations have a 
high likelihood to develop juvenile myelomonocytic leukemia (JMML),5,6 and that the 
JMML might in some cases actually be the presenting phenotype (without the presence of 
the aforementioned skin changes)7 highlighted the importance of NF1 and hyperactive RAS 
signaling in normal myeloid cell growth and also leukemogenesis in murine models.3,8
In addition to the aforementioned germline mutations, somatic mutations of NF1 are 
commonly found in human cancers.9 Furthermore, transcriptional inactivation of NF1 and 
small or large rearrangements have been identified as an important mechanism to disturb 
NF1’s function.6–8,10 While the latter mechanisms have found considerable interest in the 
acute myeloid leukemia (AML) research community, the effect of somatic gene mutations 
has largely been neglected. This might be in part due to several early studies,10–12 which 
suggested that NF1 mutations were very rare in AML. Although NF1 mutations were 
detected by the recent large sequencing efforts,13,14 the clinical correlates and possible 
prognostic and/or therapeutic implications of somatic NF1 mutations have, to our 
knowledge, not yet been assessed.
Using targeted next-generation sequencing (NGS) in a relatively large cohort of 1,021 adults 
with de novo AML, we detected recurrent mutations in NF1 in 5% of the patients. Among 
NF1 mutations, a mutation hotspot within the NF1 gene, located at amino acid threonine 676 
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(Thr676), was found in 27% of AML patients with NF1 mutations. Our data suggest that the 
presence of NF1 mutations is associated with poor outcome in younger AML patients with 
adverse genetic features and that NF1 Thr676 mutations may confer adverse prognosis.
METHODS
Patients, treatment, and cytogenetic studies
Pretreatment bone marrow (BM) or blood samples suitable for next-generation sequencing 
were obtained from 1,021 adults diagnosed with AML who were treated similarly on Cancer 
and Leukemia Group B (CALGB)/Alliance for Clinical Trials in Oncology (Alliance) trials,
15–26
 the details of which are provided in the Supplementary Information. Cytogenetic 
analyses of pretreatment BM and/or blood samples were performed by institutional, 
CALGB/Alliance-approved laboratories, and the results confirmed by central karyotype 
review.27 Patients provided written informed consent to participate in protocols CALGB 
8461 (cytogenetic studies), CALGB 9665 (leukemia tissue bank) and CALGB 20202 
(molecular studies), which involved collection of pretreatment BM and blood samples. 
Treatment protocols were in accordance with the Declaration of Helsinki and approved by 
the institutional review boards at each center, and all patients provided written informed 
consent.
Statistical analyses
Baseline characteristics were compared between patients with NF1 mutations and those with 
wild-type NF1 using Fisher’s exact test for categorical variables and the Wilcoxon rank-sum 
test for continuous variables. We used the log-rank test to test survival variables, with 
Kaplan Meier curves for illustration. A P-value of <0.05 was considered statistically 
significant. Definitions of the clinical endpoints─complete remission (CR), disease-free 
survival (DFS) and overall survival (OS)─are provided in the Supplementary Information. 
The dataset was frozen on February 13, 2017. Data collection and statistical analyses were 
performed by the Alliance Statistics and Data Center using SAS 9.4.
Molecular analyses
Mononuclear cells were enriched through Ficoll-Hypaque gradient centrifugation and 
cryopreserved until use. The mutational status of 80 protein-coding genes was determined 
centrally at The Ohio State University by targeted amplicon sequencing using two different 
gene panels on the MiSeq platform (Illumina, San Diego, CA; see Supplementary 
Information for details).28 The MuCor program29 was used for initial data analysis. Details 
about the variant calling are outlined in the Supplementary Information. In addition to the 80 
genes assessed by next-generation sequencing, testing for CEBPA mutations, was performed 
as previously described,30 thus adding up to 81 total genes assessed in our study. Only 
patients with biallelic CEBPA mutations were considered as mutated.31 Gene mutations 
were assigned to functional groups similar to those previously described by the Cancer 
Genome Atlas Research Network11 as follows: chromatin remodeling (ASXL1, BCOR, 
BCORL1, EZH2 and SMARCA2), cohesin complex (RAD21, SMC1A, SMC3 and STAG2), 
kinases (AXL, FLT3-ITD, FLT3-TKD, KIT and TYK2), methylation-related (DNMT3A, 
IDH1/2, and TET2), NPM1 (NPM1), RAS pathway (CBL, KRAS, NRAS and PTPN11), 
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spliceosome (SF3B1, SRSF2, U2AF1 and ZRSR2), transcription factors (CEBPA, ETV6, 
GATA2, IKZF1, NOTCH1 and RUNX1) and tumor suppressors (PHF6, TP53 and WT1).
Validation of the Thr676 mutation by Sanger sequencing, both of the primary samples and 
after Topo-TA cloning, was done using the following primers: NF1_676F, 5′ 
TTCCACCCTTGACTCTCAGG 3′; NF1_676R, 5′ TTGCTGACAGAGGCAAACTC 3′. 
To further exclude technical artifacts, blinded analysis of five normal samples were included 
in the sequencing as negative controls.
The presence of copy number variations (CNVs) was determined by genotyping patient 
samples with sufficient available material using Illumina Omni-Express SNP arrays, 
followed by analysis with Illumina GenomeStudio plugin cnvpartition v3.2.0. Copy-neutral 
loss of heterozygosity (CN-LOH) was set to 1Mb.
RESULTS
Frequency of NF1 mutations in AML patients
We detected 59 NF1 mutations in 52 patients among 1,021 AML patients examined, for an 
overall frequency of 5.1% (5.2% in younger and 4.8% in older patients), which is higher 
than that found in previous reports.10–12 Two, three and five different NF1 mutations were 
found in one patient each. The NF1 mutations were found throughout the gene, and 
comprised eight nonsense, 21 frame-shift and 29 missense mutations, and one in-frame 
insertion/deletion (which we combined with the missense mutations for analysis; 
Supplementary Table S1 and Figure 1a). Three of the mutations were found at locations that 
were previously described for germline neurofibromatosis patients (Supplementary Figure 
S1). We observed a relatively high incidence of the mutation hotspot at amino acid threonine 
676 (p.Thr676fs*24 [c.2026dupC], Thr676), in which the insertion of an additional cytosine 
within a mononucleotide run of 7 cytosines by polymerase strand-slippage causes a frame-
shift mutation (Figure 1b).
The mutations of all NF1 Thr676-mutated samples of which remaining DNA was available 
(9/14) were validated by Sanger sequencing, with excellent correspondence of observed 
variant allele fractions (VAFs) in the NGS analyses and peak height in Sanger sequencing 
(Supplementary Figure S2). Since the premature termination codon resulting from the 
frameshift mutation rests at least 50bp upstream from an exon-exon junction, the mutant 
transcript should be subjected to nonsense mediated decay.
The VAFs of NF1 mutations were observed at a median VAF of 0.39, suggesting that these 
mutations act as driver mutations at least in some leukemic clones (Figure 1c), which is 
consistent with the previous finding that mutations in NF1 may be present in hematopoietic 
stem cells.12 Eleven mutations were found at VAFs ≥0.70, possibly indicating loss of 
heterozygosity.
To determine if this was the case, we tested patients that harbored NF1 mutations with a 
VAF ≥0.70, as well as those whose VAF was between 0.50 and 0.69, for the presence of 
copy number variations (CNVs). Seven of 11 patients with NF1 mutations with a VAF ≥0.70 
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and 5 of 6 patients with NF1 mutations with a VAF 0.50-0.69 had material available for 
analysis. Indeed, we found evidence of copy number variations in all patients with NF1 
mutations with a VAF ≥0.70: 6 patients showed clear deletions across the NF1 gene, and one 
had a copy-neutral loss of heterozygosity of nearly all of the long arm of chromosome 17 
(17q), including NF1 locus. This confirms the notion that VAF ≥0.70 is a good indicator of 
the presence of copy number variations. In contrast, among patients with NF1 mutations 
with a VAF 0.50-0.69, only one patient harboring NF1 mutation with VAF of 0.50 had a 
deletion encompassing the NF1 locus (Supplementary Figure S3).
Finally, we attempted to assess the relative importance of NF1 mutations by comparing their 
VAFs with the VAFs of other co-occurring mutations in the additional 79 genes that were 
sequenced on our panel for each patient. Since copy number variants (CNVs) can confound 
using VAFs for clonality estimates, we limited this analysis to NF1-mutated cases with 
VAFs <0.60, and excluded NF1-mutated cases that we determined have CNVs in NF1 
(Supplementary Figure S3). To account for CNVs in other mutated genes, we excluded 
mutations with VAFs >0.60 from consideration. Moreover, we also excluded from this 
comparison those patients who harbored recurrent balanced chromosome abnormalities 
leading to gene fusions, which are clearly primary, disease defining, used in WHO-
classification, genetic rearrangements in these patients [i.e., 4 patients with inv(16)
(p13.1q22) (no. 3, 23, 24 and 52 in Supplementary Table S1); 1 patient with t(8;21)
(q22;q22) (no. 34); 3 with inv(3)(q21q26.2) (no. 20, 41 and 44) and 1 patient with t(6;9)
(p23;q34) (no. 50)]. Among the 33 NF1-mutated patients subject to this analysis, the NF1 
mutation was found in the major clone in 45% of patients (n=15; as defined by NF1 being 
the mutation with either the largest VAF, or being within 0.05 of the largest VAF gene 
mutation). In the remaining 55% of NF1-mutated patients (n=18), acquisition of the NF1 
mutation was likely a later mutational event, indicated by a lower VAF (Supplementary 
Table 2).
Clinical, cytogenetic and molecular genetic characteristics of NF1-mutated AML patients
NF1-mutated patients had a lower percentage of bone marrow (BM) blasts compared with 
NF1 wild-type patients (P<0.001), and belonged more often to the adverse risk category 
(P=0.02) in the 2017 European LeukemiaNet (ELN) risk stratification classification.31 With 
respect to pretreatment cytogenetic findings in NF1-mutated patients, normal karyotypes 
were most common [found in 19 (37%) patients], followed by complex karyotypes [10 
(19%) patients], sole +8 in at least one clone [5 (10%) patients], inv(16)(p13.1q22) [4 (8%) 
patients] and inv(3)(q21q26)/t(3;3)(q21;q26) [3 (6%) patients]. The detection of NF1 
mutations in patients harboring inv(16)(p13.1q22) and those with inv(3)(q21q26.2)/t(3;3)
(q21;q26.2) is consistent with the previous report showing mutations in genes belonging to 
the RAS pathway in patients with the aforementioned chromosome abnormalities.14 
Notably, NF1-mutated patients more often had complex karyotypes (19% vs 9%, P<0.001) 
and less frequently normal karyotypes (37% vs 54%, P=0.02) than patients with wild-type 
NF1 (Supplementary Tables S1 and S3).
We next analyzed mutations co-occurring with the NF1 mutations. NF1-mutated patients 
harbored mutations in tumor suppressor genes more often than patients with wild-type NF1 
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(29% vs 16%, P=0.02), and also tended to carry mutations in the chromatin remodeling 
genes (27% vs 16%, P=0.06). The most frequently mutated functional groups in NF1-
mutated patients were the methylation-related genes (38% of patients), kinases (33%) and 
NPM1 (35%), but their frequency did not differ significantly from those in patients with 
wild-type NF1 (Supplementary Table S4). With respect to single gene mutations, more 
common in NF1-mutated patients than in patients with wild-type NF1 were mutations in 
SF3B1 (13% vs 3%, P=0.002), IKZF1 (8% vs 1%, P=0.005), TP53 (17% vs 6%, P=0.007) 
and HNRNPK (4% vs 1%, P=0.05) genes (Supplementary Table S5).
For better visualization of the mutational spectrum of NF1-mutated patients, we created an 
oncoprint depicting both co-occurring gene mutations and cytogenetic findings of the 
patients (Figure 1d). The paucity of co-occurring biallelic CEBPA mutations in 
cytogenetically normal AML, found only in one NF1-mutated patient, and the absence of 
KIT mutations in core-binding factor AML seems noteworthy (Figure 1d).
We also assessed whether different NF1 mutation types [Thr676 hotspot mutations, other 
frameshift and/or nonsense mutations and missense mutations (including one patient with in-
frame insertion/deletion) were associated with particular clinical features and/or co-
occurring mutations. Patients with Thr676 mutations had lower presenting white blood cell 
(WBC) counts than patients with NF1 frameshift or nonsense mutations whose WBC counts 
were lower than those of patients with NF1 missense mutations (NF1 Thr676 mutations vs 
other frameshift/nonsense mutations vs missense mutations, median, 7.9 × 109/l vs 14.8 × 
109/l vs 27.2 × 109/l, P=0.02). Patients with Thr676 mutations also tended to have lower 
hemoglobin levels at time of diagnosis (8.1 g/dl vs 9.1 g/dl and 9.2 g/dl, P=0.05; 
Supplementary Table S6). Whereas no patient with NF1 Thr676 mutation and only one 
patient (9%) with other frameshift/nonsense mutations had extramedullary involvement, 10 
patients (40%) with NF1 missense mutations had extramedullary disease (P=0.007), 
including four patients with splenomegaly and five with lymphadenopathy. With regard to 
co-occurring mutations, there were no significant differences in the frequencies of gene 
mutations assigned to the functional groups among patients with the three aforementioned 
NF1 mutation types (NF1 Thr676 mutations vs other frameshift/nonsense mutations vs 
missense mutations; Supplementary Table S7).
Treatment outcome of NF1-mutated AML patients
Since patients aged <60 years and those aged ≥60 years were treated differently, the 
outcome analyses were performed separately for each age group. In younger patients, the 
presence of NF1 mutations had no significant impact on the patients’ outcome (Table 1, 
Supplementary Figures S4a and S4b).
We also compared the clinical outcome of younger patients who had NF1 mutations with 
VAF ≥0.50 (n=13) with that of younger patients with NF1 mutation VAF <0.50 (n=21), and 
found that the former had worse outcome. All 5 patients with VAF ≥0.50 who achieved a CR 
and had adequate follow-up relapsed, compared with only 35% of patients harboring NF1 
mutations with a VAF <0.50 (P=0.04). Patients with VAF ≥0.50 also had shorter overall 
survival (3-year rates, 23% vs 48%, P=0.03), and tended to have shorter disease-free survival 
(3-year rates, 0% versus 47%, P=0.09; Supplementary Table S8).
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In older patients, the presence of NF1 mutations was associated with a lower probability to 
achieve a complete remission (CR; P=0.001, Table 1), with only three of 14 (21%) NF1-
mutated patients achieving a CR compared with 168 of 283 (59%) patients with wild-type 
NF1. There was no significant difference in overall survival (OS) between older patients 
with and those without NF1 mutations (Table 1, Supplementary Figure S4d).
As NF1 mutations were most common in AML patients classified in the favorable and 
adverse risk categories according to the ELN 2017 classification,31 we investigated whether 
the presence of NF1 mutations could refine the outcomes within these risk groups. The 
outcomes of younger patients in the ELN favorable group were not affected by the presence 
of NF1 mutations (Table 2). However, younger patients in the ELN adverse risk category 
harboring NF1 mutations had a lower CR rate (20% vs 53%, P=0.05), and shorter OS 
(median, 0.4 vs 1.0 years, P<0.001) than patients with wild-type NF1. No younger NF1-
mutated patient belonging to the ELN adverse risk category who did not receive an 
allogeneic transplant was alive 1.5 years after diagnosis.
Among older patients in the ELN adverse group, there were no outcome differences between 
patients with and without NF1 mutations (Table 2). Too few older patients in the ELN 
favorable group had NF1 mutations to assess the influence of these mutations on the 
patients’ prognosis.
Lastly, we analyzed associations among the different mutation types and the patients’ 
outcome. As only 14 patients age ≥60 years were NF1 mutated, we restricted the analysis to 
patients <60 years of age. Interestingly, while the CR rates and survival of patients with 
missense mutations (n=16), or other frameshift or nonsense mutations (n=8) did not differ 
from those of patients with wild-type NF1, patients harboring the Thr676 hotspot mutation 
(n=10) had a reduced CR rate (50% vs 79%, P=0.04), and shorter OS than patients with 
wild-type NF1 (median, 0.8 vs 2.2 years, P=0.01, Figure 2b and Supplementary Table S9).
DISCUSSION
Our finding of the relatively frequent occurrence of NF1 mutations in AML patients might 
suggest a more prominent role of NF1 than previously anticipated. The higher frequency of 
NF1 mutations in our patient cohort compared with earlier studies10–12 might in part be due 
to rapidly improving sensitivity of the targeted NGS techniques. Moreover, two recent large 
NGS studies detected NF1 mutations in only 1%11 and 1.8%14 of their patients, respectively. 
Notably, neither of these two large studies11,14 captured recurrent mutations in the newly 
defined mutation hotspot Thr676, which accounts for a large proportion of mutations (24%) 
in our patient set. The most likely reason for the oversight of the mutation hotspot in 
previous studies is its location in a mononucleotide repeat, which, for example, is similar to 
the strand slippage mutation in CTCF in endometrial cancers that was also initially 
unidentified.32 In contrast, the recently published AACR GENIE dataset33 detected Thr676 
mutations in AML, thereby highlighting that the continuous advances in NGS techniques 
will continue to uncover mutations in difficult and repetitive regions. Interestingly, the 
Thr676 mutation was also previously detected in patients with juvenile myelomonocytic 
leukemia,34 thus further supporting the importance of this hotspot in leukemia. Two other 
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studies, which analyzed AML patients with heterozygous NF1 deletions for the presence of 
NF1 mutations in the remaining coding allele of the gene, only sporadically found these 
mutations, in one10 and two12 patients, respectively. A third study by Haferlach et al.13 
showed that 30% (7/23) of their NF1 deleted de novo AML cases harbored NF1 mutations. 
However, the Thr676 hotspot was not listed among these mutations.13 However, despite 
advances in sequencing and variant-calling techniques, a continuous careful evaluation of 
sequencing data to exclude filtering of such variants will likely still be necessary in the 
future.
To our knowledge, this is the first report of an adverse prognostic impact of NF1 mutations 
in younger de novo AML patients classified in the ELN adverse risk group and in patients 
who harbored NF1 Thr676 mutations. A previous study assessing the prognostic impact of 
NF1 deletions in de novo AML found no statistically significant differences in CR rates, 3-
year relapse-free and overall survival.10 However, Boudry-Labis et al.,10 who performed 
mutation screening only in NF1-deleted patients, detected only one NF1 Thr676 mutation in 
their patients, and did not analyze the data in the context of such a prognostic classification 
as the ELN classification used in our study.
The number of patients analyzed in our study was relatively small, and they were 
heterogeneous with regard to cytogenetic findings. Thus our findings require corroboration. 
If confirmed, testing for NF1 mutations might provide additional prognostic information 
both in AML patients aged <60 years, especially if NF1 mutation is found at a VAF of 
≥0.50, and in patients ≥60 years of age. The particularly poor outcome of NF1-mutated 
patients belonging to the ELN adverse risk category suggests that NF1 mutation status could 
be considered as part of the mutational risk assessment. Given the importance of VAF in 
younger patients, and the difficulty assessing the Thr676 mutation hotspot, it might be 
necessary to use next generation sequencing techniques with high sensitivities in repetitive 
regions, like the Miseq used in our analysis.
Our findings both with respect to the frequency, the mutation hotspot and the observed 
adverse prognostic impact of the NF1 mutations may be of potential importance in view of 
targeted treatment approaches. While Nf1-deficient AML cell lines were shown to confer 
cytarabine resistance,35 loss or inactivation of NF1 have been previously demonstrated to 
increase sensitivity to rapamycin-induced apoptosis, suggesting mTOR-directed therapeutics 
as possible targeted therapeutic options in presence of the NF1 null state.12
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Mutations in the NF1 gene found in 1,021 patients with de novo acute myeloid leukemia. (a) 
Lollipop plots depicting 59 NF1 mutations detected in 52 patients. No. denotes number; aa, 
amino acid. (b) Sanger sequencing traces depicting examples of NF1 amino acid Threonine 
(Thr) 676 wild-type (top) and mutated (bottom) AML cases. (c) Beehive plot depicting 
variant allele fractions of the detected NF1 mutations. (d) Oncoprint of co-occurring 
mutations found in at least two AML patients with NF1 mutations (blue color), and of genes 
classified into the previously described functional groups.11 Each column represents an 
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individual patient. Red color indicates that a gene was found to be mutated in the patient, 
white indicates wild-type status of the gene. The patients are grouped according to their 
pretreatment cytogenetic findings. The following genes also found to be mutated are not 
depicted in the oncoprint because they were detected in single patients (i.e., with a frequency 
below 2%): AXL and TYK2 (kinases); PHF6 (tumor suppressors); SRSF2 (splicesome); 
SF1 and SF3A3 (chromatin remodeling); STAG2 (cohesin complex); and CEBPA, ETV6 
and NOTCH1 (transcription factors).
Eisfeld et al. Page 13
Leukemia. Author manuscript; available in PMC 2018 December 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
Kaplan-Meyer curves depicting overall survival of patients with de novo AML according to 
the presence or absence of NF1 mutations. (a) Patients <60 years of age belonging to the 
ELN 2017 adverse risk group with any NF1 mutation (red) compared with patients without 
NF1 mutations (blue). (b) Patients <60 years of age with NF1 Thr676 mutations (red) 
compared with patients without these mutations (blue).
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Table 1
Outcomes of AML patients with and without NF1 mutations separately listed for patients aged <60 years and 
those aged ≥60 years
AML patients <60 years
Endpoint NF1 mutated(n=34)a
NF1 wild-type
(n=586) P-valueb
Complete remission, n (%) 23 (68) 463 (79) 0.13
Relapse rate, n (%) 11 (50)c 276 (60) 0.38
Disease-free survival
 Mutated patients (number of eventsd) 22 (15) 457 (309)
0.78
 Median, years 1.5 1.4
 % Disease-free at 1 year (95% CI) 59 (36-76) 57 (52-61)
 % Disease-free at 3 years (95% CI) 36 (17-56) 38 (34-42)
Overall survival
 Mutated patients (number of eventse) 34 (25) 586 (375)
0.12
 Median, years 1.6 2.2
 % Alive at 1 year (95% CI) 62 (43-76) 71 (67-75)
 % Alive at 3 years (95% CI) 38 (22-54) 45 (41-49)
AML patients ≥60 years
Endpoint NF1 mutated(n=14)a
NF1 wild-type
(n=283) P-valueb
Complete remission, n (%) 3 (21) 168 (59) 0.001
Relapse rate, n (%) 3 (100) 139 (84) 1.00
Disease-free survival
 Mutated patients (number of eventsd) 3 (3) 166 (154)
–
 Median, years 0.6 0.6
 % Disease-free at 1 year (95% CI) 0 34 (27-41)
 % Disease-free at 3 years (95% CI) 0 14 (9-20)
Overall survival
 Mutated patients (number of eventse) 14 (13) 283 (266)
0.11
 Median, years 0.4 0.8
 % Alive at 1 year (95% CI) 14 (2-37) 41 (35-47)
 % Alive at 3 years (95% CI) 14 (2-37) 15 (12-20)
Abbreviations: CI, confidence interval; n, number.
a
Patients who received allogeneic hematopoietic stem cell transplantation while in first CR (n=3) or did not receive post-remission chemotherapy 
according to protocol (n=1) were excluded from the outcome analyses.
bP-values for categorical variables are from Fisher’s exact test, P-values for time to event variables are from the log-rank test.
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cOne patient who achieved a CR was lost to follow-up.
dAn event for DFS is relapse or death, patients alive and relapse-free at last follow-up are censored.
eAn event for OS is death and patients alive at last follow-up are censored.
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Table 2
Outcomes of younger (aged <60 years) and older (aged ≥60 years) AML patients with and without NF1 
mutations classified into the ELN favorable or adverse risk groups
AML patients <60 years classified in the ELN favorable risk group
Endpoint NF1 mutated(n=18)a
NF1 wild-type
(n=297)a P-value
b
Complete remission, n (%) 18 (100) 272 (92) 0.38
Disease-free survival‡ 0.84
 Median, years 3.1 4.9
 % Disease-free at 1 year (95% CI) 72 (46-87) 68 (62-73)
 % Disease-free at 3 years (95% CI) 50 (26-70) 52 (46-58)
Overall survival‡ 0.37
 Median, years 4.3 13.0
 % Alive at 1 year (95% CI) 83 (57-94) 85 (80-88)
 % Alive at 3 years (95% CI) 56 (31-75) 65 (59-70)
AML patients <60 years classified in the ELN adverse risk group
Endpoint NF1 mutated(n=10)a
NF1 wild-type
(n=124)a P-valueb
Complete remission, n (%) 2 (20) 66 (53) 0.05
Disease-free survivalc –
 Median, years 0.4 0.7
 % Disease-free at 1 year (95% CI) 0 36 (25-48)
 % Disease-free at 3 years (95% CI) 0 12 (6-21)
Overall survivalc <0.001
 Median, years 0.4 1.0
 % Alive at 1 year (95% CI) 20 (3-47) 51 (42-59)
 % Alive at 3 years (95% CI) 0 22 (15-29)
AML patients ≥60 years classified in the ELN adverse risk group
Endpoint NF1 mutated(n=10)a
NF1 wild-type
(n=93)a P-valueb
Complete remission, n (%) 2 (20) 39 (42) 0.31
Disease-free survivalc –
 Median, years 0.4 0.4
 % Disease-free at 1 year (95% CI) 0 21 (10-35)
 % Disease-free at 3 years (95% CI) 0 0
Overall survivalc 0.48
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AML patients <60 years classified in the ELN favorable risk group
Endpoint NF1 mutated(n=18)a
NF1 wild-type
(n=297)a P-value
b
 Median, years 0.4 0.6
 % Alive at 1 year (95% CI) 10 (1-36) 27 (18-36)
 % Alive at 3 years (95% CI) 10 (1-36) 4 (1-10)
Abbreviations: CI, confidence interval; ELN, European LeukemiaNet; n, number.
aAmong patients who achieved a CR, only those who received at least one cycle of postremission chemotherapy according to protocol were 
included in the outcome analysis.
bP-values for complete remission are from Fisher’s exact test, P-values for disease-free and overall survival are from the log-rank test.
c
Patients who received allogeneic hematopoietic stem cell transplantation in first CR were excluded from disease-free survival and overall survival 
analyses.
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